Brain regions that deteriorate earliest in Huntington's disease may not necessarily accumulate the most toxic protein fragments, challenging assumptions about how this devastating neurological disorder progresses. This finding could reshape therapeutic strategies that have focused on clearing mutant huntingtin protein from the brain.
Using specialized antibodies targeting the P90 neoepitope of mutant huntingtin exon 1 protein (HTT1a), researchers mapped protein distribution across mouse models and human brain tissue. In Q175 mice, striatal projection neurons—among the first to die in Huntington's—showed early HTT1a accumulation, while cortical neurons displayed delayed buildup. However, the hippocampus, which remains relatively preserved in the disease, also contained substantial amounts of the mutant protein. Human brain samples revealed sparser striatal labeling compared to mice, with protein aggregates predominantly found in neural projections rather than cell bodies.
This research illuminates a critical paradox in neurodegeneration: protein accumulation alone does not predict cellular vulnerability. The disconnect suggests that individual brain regions and neuron types possess varying capacities to tolerate mutant huntingtin, potentially through differences in cellular clearance mechanisms, metabolic resilience, or protective factors. Such regional variation implies that successful Huntington's therapies may need to account for tissue-specific responses rather than applying uniform protein-clearing approaches. The findings also highlight important species differences between mouse models and human disease, emphasizing the need for human-relevant research in developing treatments. Understanding why some neurons succumb while others survive despite similar protein burdens could unlock new therapeutic avenues focused on enhancing cellular resilience rather than merely reducing protein levels.